Healthcare / BiotechnologyStockholm
$19.62
-0.48 (-2.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $32.3M · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
53.0x
↑EV/EBITDA
28.0x
↑ROE
8.7%
↑Gross Margin
89.8%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.0%
FCF CAGR
—
FCF margin
15.1%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $128.9M · net income $23.5M · FCF $19.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $128.9M | $128.9M | $130.4M | $158.2M | $102.4M |
| Net Income | $23.5M | $23.5M | $32.9M | $61.5M | $11.2M |
| EBITDA | $42.9M | $42.9M | $60.7M | $66.8M | $15.0M |
| EPS | 0.36 | 0.36 | 0.50 | 0.94 | 0.17 |
| Gross Margin | 89.8% | 89.8% | 88.2% | 90.4% | 85.3% |
| Operating Margin | 21.6% | 21.6% | 22.6% | 34.7% | 13.5% |
| Net Margin | 18.2% | 18.2% | 25.3% | 38.9% | 10.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.34 | 0.42 | 0.06 |
| Current Ratio | 7.65 | 7.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $19.5M | $19.5M | $32.3M | $54.9M | $-4.8M |
| Returns | |||||
| ROE | 8.7% | 8.7% | 14.4% | 32.2% | 8.9% |
| Valuation | |||||
| P/E | 53.03 | 53.03 | 47.30 | 54.79 | 256.76 |
| EV/EBITDA | 28.01 | 28.01 | 23.97 | 49.79 | 186.56 |
| P/B | 4.75 | 4.75 | 6.79 | 17.67 | 22.74 |
| Growth & Yield | |||||
| Revenue Growth | -1.1% | -1.1% | -17.6% | 54.5% | — |
| EPS Growth | -28.0% | -28.0% | -46.8% | 452.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
69.1%
EPS terminal req.
$1.74
Spread vs growth
-97.1%
5Y implied EPS CAGR
42.4%
EPS terminal req.
$2.11
Spread vs growth
-70.4%
10Y implied EPS CAGR
25.1%
EPS terminal req.
$3.39
Spread vs growth
-53.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.2%
Start / end P/E
53.9x → 54.5x
EPS bridge
0.50 → 0.36
Residual
-0.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.